Search - tctmd.com

Displaying 81 - 100 of 823

Sort: Relevancy | Date

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

DRAMI: No Clear Winner for Distal vs Traditional Radial Access in STEMI

News Conference News TCT 2024

DRAMI: No Clear Winner for Distal vs Traditional Radial Access in STEMI

October 29, 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

October 28, 2024

At EACTS 2024, Surgeons and Cardiologists Move Past EXCEL Firestorm

News Conference News EACTS 2024

At EACTS 2024, Surgeons and Cardiologists Move Past EXCEL Firestorm

Yael L. Maxwell

October 22, 2024

Enhanced Recovery After Cardiac Surgery: Fewer Complications, Shorter Stays

News Conference News EACTS 2024

Enhanced Recovery After Cardiac Surgery: Fewer Complications, Shorter Stays

Yael L. Maxwell

October 16, 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

News Conference News HFSA 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

October 03, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

More Data Diminish Support for Cath Lab Fasting Rules: SCOFF

News Conference News ESC 2024

More Data Diminish Support for Cath Lab Fasting Rules: SCOFF

September 10, 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

News Conference News ESC 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

September 10, 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

September 09, 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

News Conference News ESC 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

September 06, 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

News Conference News ESC 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

September 06, 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

News Conference News ESC 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Yael L. Maxwell

September 04, 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

News Conference News ESC 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

September 04, 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

News Conference News ESC 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

September 03, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.